12:00 AM
 | 
Aug 24, 2015
 |  BC Week In Review  |  Company News  |  Deals

New Zealand Pharmaceuticals, Fortress Biotech deal

New Zealand granted Fortress’ Altamira Bio subsidiary exclusive, worldwide rights to develop ManNAc to treat hereditary inclusion body myopathy (HIBM) and nephropathy....

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >